These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26676948)

  • 1. Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
    Li X; Zhang R; Zhao B; Lossin C; Cao Z
    Arch Toxicol; 2016 Aug; 90(8):1803-16. PubMed ID: 26676948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
    Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
    Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of extracellular field potential and Ca
    Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
    J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays.
    Gilchrist KH; Lewis GF; Gay EA; Sellgren KL; Grego S
    Toxicol Appl Pharmacol; 2015 Oct; 288(2):249-57. PubMed ID: 26232523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.
    Lu HR; Whittaker R; Price JH; Vega R; Pfeiffer ER; Cerignoli F; Towart R; Gallacher DJ
    Toxicol Sci; 2015 Dec; 148(2):503-16. PubMed ID: 26358003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety assessment with motion field imaging analysis of human iPS cell-derived cardiomyocytes is improved by an integrated evaluation with cardiac ion channel profiling.
    Isobe T; Honda M; Komatsu R; Tabo M
    J Toxicol Sci; 2019; 44(12):859-870. PubMed ID: 31813905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes.
    Tertoolen LGJ; Braam SR; van Meer BJ; Passier R; Mummery CL
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1135-1141. PubMed ID: 28153730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction.
    Stoelzle S; Haythornthwaite A; Kettenhofen R; Kolossov E; Bohlen H; George M; Brüggemann A; Fertig N
    J Biomol Screen; 2011 Sep; 16(8):910-6. PubMed ID: 21775699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
    Qu Y; Gao B; Fang M; Vargas HM
    J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes.
    Jans D; Callewaert G; Krylychkina O; Hoffman L; Gullo F; Prodanov D; Braeken D
    J Pharmacol Toxicol Methods; 2017 Sep; 87():48-52. PubMed ID: 28549786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of strategies to improve preclinical cardiac safety testing.
    Gintant G; Sager PT; Stockbridge N
    Nat Rev Drug Discov; 2016 Jul; 15(7):457-71. PubMed ID: 26893184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.
    Kraushaar U; Meyer T; Hess D; Gepstein L; Mummery CL; Braam SR; Guenther E
    Expert Opin Drug Saf; 2012 Mar; 11(2):285-98. PubMed ID: 22103746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.